Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

The controversial role of serum uric acid in essential hypertension: relationships with indices of target organ damage

Journal of Human Hypertension volume 19, pages 211–217 (2005)Cite this article

Abstract

The role of serum uric acid (SUA) in the context of adverse cardiovascular events in hypertensive subjects is controversial. Additionally, the relationship between SUA and indices of target organ damage is not well defined in this setting. Towards this end, we studied 842 consecutive nondiabetic patients with stage I–II essential hypertension (office blood pressure=148/95 mmHg, aged 53.4 years), referred to our outpatient hypertensive unit within a period of 4 years. According to the urinary albumin excretion (UAE), the study population was classified into those with microalbuminuria [MA(+), UAE=20–200 mg/24 h, n=222] and those without MA [MA (−), UAE< 20 mg/24 h, n=620]. Moreover, according to the presence of left ventricular hypertrophy (LVH) the participants were subdivided into two additional groups: [LVH (+), n=305 and LVH (−), n=537]. SUA levels were higher by 0.4 mg/dl, (P=0.04) in group MA (+) compared with the group MA (−), while no difference was observed between groups LVH (+) and LVH (−) (P=NS). In the entire population, SUA was correlated with body mass index (BMI) (r=0.17, P<0.001), waist/hip ratio (r=0.3, P<0.001), office systolic blood pressure (SBP) (r=0.14, P<0.05), triglycerides levels (r=0.25, P<0.001), UAE (r=0.35, P<0.001) and HDL (r=−0.26, P<0.001). Multiple regression analysis demonstrated that SUA was significantly related with BMI, office SBP and UAE (P<0.05). In conclusion, increased SUA levels are associated with MA but not with LVH in essential hypertensive subjects. Whether these inter-relationships may elucidate the clinical positioning of augmented SUA in this setting remains to be clarified in future studies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.

  2. Persky VW et al. Uric acid: a risk factor for coronary heart disease? Circulation 1979; 59: 969–977.

    Article  CAS  Google Scholar 

  3. Lehto S, Niskanen L, Ronnemaa T, Laakso M . Serum uric acid is a strong predictor of stroke in patients with non-dependent diabetes mellitus. Stroke 1998; 29: 635–639.

    Article  CAS  Google Scholar 

  4. Levine W et al. Serum uric acid and 11.5 year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol 1989; 42: 257–267.

    Article  CAS  Google Scholar 

  5. Frohlich ED . Uric acid: a risk factor for coronary heart disease. JAMA 1993; 270: 378–379.

    Article  CAS  Google Scholar 

  6. Ward HJ . Uric acid as an independent risk factor in the treatment of hypertension. Lancet 1998; 352: 670–671.

    Article  CAS  Google Scholar 

  7. Wannamethee SG, Shaper AG, Whincup PH . Serum urate and the risk of major coronary heart disease events. Heart 1997; 78: 147–153.

    Article  CAS  Google Scholar 

  8. Fessel WJ . High uric acid as an indicator of cardiovascular disease: independence from obesity. Am J Med 1980; 68: 401–404.

    Article  CAS  Google Scholar 

  9. Brand FN et al. Hyperuricemia as a risk factor of coronary heart disease: the Framingham study. Am J Epidemiol 1985; 121: 11–18.

    Article  CAS  Google Scholar 

  10. Culleton BF, Larson MG, Kannel WB, Levy D . Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131: 7–13.

    Article  CAS  Google Scholar 

  11. Puig JG, Ruilope LM . Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens 1999; 17: 869–872.

    Article  CAS  Google Scholar 

  12. Jaques BC, Ginsberg MH . The role of cell surface proteins in platelet stimulation by monosodium urate crystals. Arthritis Rheum 1982; 25: 508–521.

    Article  CAS  Google Scholar 

  13. Chapman PT et al. Endothelial activation in monosodium urate monohydrate crystal – induced inflammation: in vitro and in vivo studies on the role of tumor necrosis factor alpha and interleukin-1. Arthritis Rheum 1997; 40: 955–965.

    Article  CAS  Google Scholar 

  14. Leoncini G et al. Microalbuminuria is an integrated marker of subclinical organ damage in primary hypertension. J Hum Hypertens 2002; 16: 399–404.

    Article  CAS  Google Scholar 

  15. Sica DA, Weber D . The Losartan Intervention for Endpoint Reduction (LIFE) trial—have angiotensin receptor blockers come of age? J Clin Hypertens 2002; 4: 301–305.

    Article  Google Scholar 

  16. The Joint National Committee on detection, evaluation and treatment of high blood pressure. The sixth report of the Joint National Committee on detection, evaluation and treatment of high blood pressure (JNC VI). Arch Intern Med 1997; 157: 2413–2446.

  17. Schiller NB et al. Recommendations for quantitation of the left ventricular dimensions by two-dimensional echocardiography, American Society of Echocardiography Committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 1989; 2: 358–367.

    Article  CAS  Google Scholar 

  18. Schiller NB . Two-dimensional echocardiographic determination of left ventricular volume, systolic function, and mass. Summary and discussion of the 1989 recommendations of the American Society of Echocardiography. Circulation 1991; 84: 1280–1287.

    Google Scholar 

  19. Agrawal B, Berger A, Wolf K, Luft FC . Microalbuminuria screening by reagent strips predicts cardiovascular risk in hypertension. J Hypertens 1996; 14: 223–228.

    Article  CAS  Google Scholar 

  20. Modan M, Halkin H, Karasik A, Lusky A . Elevated serum uric acid: a facet of hyperinsulinemia. Diabetologia 1987; 30: 713–718.

    Article  CAS  Google Scholar 

  21. Kuusisto J, Mykkanen L, Pyorala K, Laakso M . Hyperinsulinemic microalbuminuria: a new risk indicator for coronary heart disease. Circulation 1995; 91: 831–837.

    Article  CAS  Google Scholar 

  22. Modan M et al. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest 1985; 75: 809–817.

    Article  CAS  Google Scholar 

  23. Niskanen L, Laakso M . Insulin resistance is related to albuminuria in patients with type II (non-insulin-dependent) diabetes mellitus. Metabolism 1993; 42: 1541–1545.

    Article  CAS  Google Scholar 

  24. Saad MF et al. Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med 1991; 324: 733–739.

    Article  CAS  Google Scholar 

  25. Berry CE, Hare JM . Xanthine oxidoreductase and cardiovascular disease—molecular mechanisms and pathophysiologic implications. J Physiol 2004; 555(Part 3): 589–606.

    Article  CAS  Google Scholar 

  26. Sesso HD et al. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290: 2945–2951.

    Article  CAS  Google Scholar 

  27. Kanellis J et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen—activated protein kinase and cyclooxygenase-2. Hypertension 2003; 41: 1287–1293.

    Article  CAS  Google Scholar 

  28. Di Bello V et al. Microalbuminuria, pulse pressure, left ventricular hypertrophy, and myocardial ultrasonic tissue characterization in essential hypertension. Angiology 2001; 52: 175–183.

    Article  CAS  Google Scholar 

  29. Dell’omo G et al. Blood pressure independent association of microalbuminuria and left ventricular hypertrophy in hypertensive men. J Intern Med 2003; 254: 76–84.

    Article  Google Scholar 

  30. Ravera M et al. Microalbuminuria and subclinical cerebrovascular damage in essential hypertension. J Nephrol 2002; 15: 519–524.

    PubMed  Google Scholar 

  31. Tsioufis C et al. Inter-relationships of microalbuminuria with the other surrogates of the atherosclerotic cardiovascular disease in hypertensive subjects. Am J Hypertens 2004; 17: 470–476.

    Article  CAS  Google Scholar 

  32. Tsioufis C et al. Microalbuminuria is associated with unfavourable cardiac geometric adaptations in essential hypertensive patients. J Hum Hypertens 2002; 16: 249–254.

    Article  CAS  Google Scholar 

  33. Tsioufis C et al. Relation of ambulatory blood pressure load with left ventricular geometry in untreated patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13: 677–682.

    Article  CAS  Google Scholar 

  34. Tsioufis C et al. Microalbuminuria is associated with impaired arterial mechanics in essential hypertension. Am J Cardiol 2000; 86: 797–801.

    Article  CAS  Google Scholar 

  35. Alderman MH, Cohen H, Madhavan S, Kivlighn S . Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34: 144–150.

    Article  CAS  Google Scholar 

  36. Staessen J . The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly trial. Am J Med 1991; 90: 50S–54S.

    Article  CAS  Google Scholar 

  37. Franse LV et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18: 1149–1154.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Athens University, Hippokration Hospital, Athens, Greece

    C Tsioufis, D Chatzis, E Vezali, K Dimitriadis, D Antoniadis, A Zervoudaki, S Lalos, I Kallikazaros, C Stefanadis & P Toutouzas

Authors
  1. C Tsioufis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Chatzis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E Vezali
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Dimitriadis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Antoniadis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Zervoudaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Lalos
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. I Kallikazaros
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C Stefanadis
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. P Toutouzas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Tsioufis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tsioufis, C., Chatzis, D., Vezali, E. et al. The controversial role of serum uric acid in essential hypertension: relationships with indices of target organ damage. J Hum Hypertens 19, 211–217 (2005). https://doi.org/10.1038/sj.jhh.1001810

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001810

Keywords

This article is cited by

Search

Advanced search

Quick links